Gadobenate dimeglumine

Drug Profile

Gadobenate dimeglumine

Alternative Names: B-19036; B-19036/7; E 7155; Gadobenic acid; Gd-BOPTA/Dimeg; MultiHance

Latest Information Update: 02 May 2017

Price : $50

At a glance

  • Originator Bracco Diagnostics
  • Class Diagnostic agents; Gadolinium-containing contrast agents; Hexosamines; Organometallic compounds; Small molecules; Sugar alcohols
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Arterial occlusive disorders; CNS disorders

Most Recent Events

  • 10 Mar 2017 EMA's Pharmacovigilance Risk Assessment Committee recommends suspension of gadobenate dimeglumine from the market in the European Union
  • 27 Jul 2012 Launched for Arterial occlusive disorders (diagnosis) in USA (IV)
  • 07 Mar 2012 Diagnostic efficacy data from the MERIT trial for CNS disorders released by Bracco Diagnostics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top